BLB(SZ:002286)2021-04-28 16:00Financial Performance - The company's revenue for Q1 2021 was ¥554,900,133.35, representing a 38.41% increase compared to ¥400,896,123.97 in the same period last year[8] - Net profit attributable to shareholders decreased by 37.04% to ¥8,828,328.31 from ¥14,022,940.70 year-on-year[8] - The net profit after deducting non-recurring gains and losses fell by 51.63% to ¥5,738,709.86 compared to ¥11,863,037.91 in the previous year[8] - Operating revenue increased by 38.4% compared to the same period last year, primarily due to increased product sales[19] - Operating costs rose by 43.9% year-on-year, mainly driven by the increase in sales revenue[19] - The company reported a decrease in gross profit margin due to significant increases in raw material prices[17] - The company expects net profit for the first half of 2021 to be between 4,773.27 million and 6,509.01 million yuan, representing a year-on-year increase of 10.00% to 50.00%[25] - Basic earnings per share are projected to be between 0.13 and 0.18 yuan, indicating a growth of 10.00% to 50.00% compared to the previous year[25] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 71.48% to ¥46,468,413.92 from ¥162,922,971.69 year-on-year[8] - The net cash flow from financing activities increased by ¥168,460,710.20 year-on-year, attributed to a decrease in the amount of loans repaid[18] - The cash flow from operating activities generated a net amount of CNY 46,468,413.92, down from CNY 162,922,971.69 in the prior year[51] - Cash inflow from financing activities amounted to CNY 133,000,000.00, while cash outflow was CNY 115,714,306.48, resulting in a net cash flow of CNY 17,285,693.52[55] - The net increase in cash and cash equivalents was CNY 17,309,774.65, contrasting with a decrease of CNY 14,047,063.67 in the previous period[55] Assets and Liabilities - Total assets increased by 7.34% to ¥2,807,839,828.45 from ¥2,615,727,298.11 at the end of the previous year[8] - Current assets reached CNY 1,200,988,982.90, up from CNY 1,008,155,742.62, indicating a rise of about 19.14%[33] - Total liabilities were CNY 1,200,318,381.00, up from CNY 1,016,367,838.48, reflecting an increase of about 18.06%[35] - The company's equity attributable to shareholders reached CNY 1,607,521,447.45, slightly up from CNY 1,599,359,459.63, indicating a growth of approximately 0.76%[36] - The company reported a significant increase in contract liabilities to CNY 38,141,491.87 from CNY 20,298,549.21, which is an increase of approximately 88.06%[35] Other Income and Expenses - Other income increased by 30.9% year-on-year, attributed to higher government subsidies received during the period[19] - Research and development expenses for Q1 2021 were CNY 1,760,718.02, compared to CNY 1,804,553.11 in the previous period, showing a slight decrease[42] - The company reported a total comprehensive income of CNY 7,975,787.69 for Q1 2021, down from CNY 16,876,835.82 in the previous period[44] - The company incurred a credit impairment loss of CNY 2,701,953.42, compared to a gain of CNY 1,705,733.16 in the previous year[47] - The company reported a decrease in income tax expenses to CNY 1,392,656.90 from CNY 2,026,768.46 in the previous year[47] Future Outlook - The company is focusing on health consumption demand growth and effective management measures to drive performance improvement[25] - The company did not undergo an audit for the first quarter report, indicating that the figures presented are unaudited[57] - The company did not apply the new leasing standards for the first quarter of 2021, which may affect future financial reporting[56]